|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZIM3 |
Gene summary for ZIM3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZIM3 | Gene ID | 114026 |
| Gene name | zinc finger imprinted 3 | |
| Gene Alias | ZNF264 | |
| Cytomap | 19q13.43 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96PE6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 114026 | ZIM3 | HCC1 | Human | Liver | HCC | 1.08e-05 | 5.88e-01 | 0.5336 |
| 114026 | ZIM3 | HCC2 | Human | Liver | HCC | 4.05e-12 | 9.81e-01 | 0.5341 |
| 114026 | ZIM3 | HCC5 | Human | Liver | HCC | 3.09e-02 | 6.24e-01 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZIM3 | SNV | Missense_Mutation | rs267605724 | c.1132C>T | p.Leu378Phe | p.L378F | Q96PE6 | protein_coding | tolerated(0.06) | possibly_damaging(0.663) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | |
| ZIM3 | SNV | Missense_Mutation | rs565341168 | c.158C>T | p.Thr53Ile | p.T53I | Q96PE6 | protein_coding | tolerated(0.38) | benign(0.068) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| ZIM3 | SNV | Missense_Mutation | c.368N>G | p.Ser123Cys | p.S123C | Q96PE6 | protein_coding | tolerated(0.09) | possibly_damaging(0.891) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZIM3 | SNV | Missense_Mutation | c.148N>A | p.Gly50Arg | p.G50R | Q96PE6 | protein_coding | tolerated(0.54) | benign(0) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZIM3 | SNV | Missense_Mutation | c.1408N>T | p.His470Tyr | p.H470Y | Q96PE6 | protein_coding | deleterious(0) | possibly_damaging(0.581) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZIM3 | SNV | Missense_Mutation | c.726N>C | p.Gln242His | p.Q242H | Q96PE6 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZIM3 | SNV | Missense_Mutation | c.431N>T | p.Asn144Ile | p.N144I | Q96PE6 | protein_coding | deleterious(0.03) | benign(0.285) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZIM3 | SNV | Missense_Mutation | novel | c.73C>G | p.Leu25Val | p.L25V | Q96PE6 | protein_coding | deleterious(0.01) | possibly_damaging(0.484) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
| ZIM3 | SNV | Missense_Mutation | rs376866859 | c.70N>T | p.Arg24Trp | p.R24W | Q96PE6 | protein_coding | tolerated(0.13) | benign(0) | TCGA-C8-A3M8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
| ZIM3 | insertion | Frame_Shift_Ins | novel | c.248_249insA | p.Asn83LysfsTer27 | p.N83Kfs*27 | Q96PE6 | protein_coding | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |